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ABSTRACT
Background: Tumour necrosis factor a (TNFa)i sa
proinflammatory cytokine involved in the pathogenesis of
rheumatoid arthritis (RA). Treatment with TNFa inhibitors
reduces disease activity and improves outcomes for
patients with RA. This study evaluated the efficacy and
safety of certolizumab pegol 400 mg, a novel, poly-
(ethylene glycol) (PEG)ylated, Fc-free TNFa inhibitor, as
monotherapy in patients with active RA.
Methods: In this 24-week, multicentre, randomised,
double-blind, placebo-controlled study, 220 patients
previously failing >1 disease-modifying antirheumatic
drug (DMARD) were randomised 1:1 to receive sub-
cutaneous certolizumab pegol 400 mg (n=111) or
placebo (n=109) every 4 weeks. The primary endpoint
was 20% improvement according to the American College
of Rheumatology criteria (ACR20) at week 24. Secondary
endpoints included ACR50/70 response, ACR component
scores, 28-joint Disease Activity Score Erythrocyte
Sedimentation Rate 3 (DAS28(ESR)3), patient-reported
outcomes (including physical function, health-related
quality of life (HRQoL), pain and fatigue) and safety.
Results: At week 24, the ACR20 response rates were
45.5% for certolizumab pegol 400 mg every 4 weeks vs
9.3% for placebo (p,0.001). Differences for certolizumab
pegol vs placebo in the ACR20 response were statistically
significant as early as week 1 through to week 24
(p,0.001). Significant improvements in ACR50, ACR
components, DAS28(ESR)3 and all patient-reported out-
comes were also observed early with certolizumab pegol
and were sustained throughout the study. Most adverse
events were mild or moderate and no deaths or cases of
tuberculosis were reported.
Conclusions: Treatment with certolizumab pegol
400 mg monotherapy every 4 weeks effectively reduced
the signs and symptoms of active RA in patients
previously failing >1 DMARD compared with placebo,
and demonstrated an acceptable safety profile.
Trial registration number: NCT00548834.
Tumour necrosis factor a (TNFa) inhibitors
represent a major advance in rheumatoid arthritis
(RA) treatment and are the first choice in biological
therapy for patients following an inadequate
response to non-biological disease-modifying anti-
rheumatic drugs (DMARDs).
1–5 Although all cur-
rent TNFa inhibitors have demonstrated similar
efficacy in RA clinical trials, individual patient
responses to any one or all of these agents vary in
clinical practice. Some patients also stop respond-
ing to these agents over time or discontinue
treatment due to tolerability issues.
67
Certolizumab pegol is the first poly (ethylene
glycol) (PEG)ylated, Fc-free anti-TNFa.
Attachment of a PEG chain to the Fab9 fragment
increases its half life to a mean of 14 days.
8 The
lack of an Fc portion may avoid potential Fc-
mediated effects such as complement-dependent or
antibody-dependent cell-mediated cytotoxicity as
seen in vitro.
8 In two studies, certolizumab pegol
200 mg administered every 2 weeks with conco-
mitant methotrexate (MTX) significantly reduced
the clinical signs and symptoms of RA, inhibited
the progression of structural damage and improved
physical function. Improvements in clinical effi-
cacy and inhibition of structural damage were
statistically significant at weeks 24 and 52 and were
observed as early as weeks 1 and 16, respectively.
91 0
Despite evidence of additional efficacy when
TNFa inhibitors are combined with MTX, some
patients cannot tolerate MTX or have a contra-
indication to it.
11 12 Anti-TNFa monotherapy has
been shown to be effective in the treatment of
RA.
21 31 4 Here we present results from the
FAST4WARD (for ‘‘eFficAcy and Safety of
cerTolizumab pegol – 4 Weekly dosAge in
RheumatoiD arthritis’’) study, which examined the
efficacy (signs and symptoms and patient-reported
outcomes) and safety of certolizumab pegol 400 mg
monotherapy, administered subcutaneously every
4 weeks, vs placebo in patients with RA who had
failed at least one prior DMARD.
METHODS
Patients
Eligible patients, aged 18–75 years, had adult
onset RA, defined by the 1987 American College
of Rheumatology (ACR) criteria
15 of duration
>6 months, and had failed >1 prior DMARD
due to lack of efficacy or intolerance. Subjects had
to have active disease at screening and baseline,
defined by >9 (out of 68) tender joints and >9 (out
of 66) swollen joints and >1 of the following:
>45 min of morning stiffness, erythrocyte sedimen-
tation rate (ESR; Westergren method) >28 mm/h,
or C-reactive protein (CRP) .10 mg/litre. DMARDs
were discontinued for >28 days or five half lives of
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first study dose, except for leflunomide, which was eliminated
using cholestyramine administration followed by a further 28-day
washout.
Patients were excluded if they had any inflammatory arthritis
other than RA or a history of chronic, serious or life-threatening
infection, any current infection, a history of or a chest x ray
suggesting tuberculosis or a positive (defined by local practice)
purified protein derivative (PPD) skin test. Patients positive for
PPD who had received the Bacille Calmette-Gue ´rin (BCG)
vaccination and had a negative chest x ray and no clinical
symptoms of tuberculosis could be enrolled.
Patients who had received biological therapies for RA within
6 months, or prior treatment with TNFa inhibitors, were
excluded. Concurrent oral corticosteroids (prednisone equiva-
lent (10 mg/day, stable for >4 weeks prior to enrolment and
during the study), non-steroidal anti-inflammatory drugs and
analgesics were allowed. Intra-articular, periarticular, intramus-
cular and intravenous corticosteroids were prohibited.
Study design
FAST4WARD was a 24-week, randomised, double-blind, placebo-
controlled study conducted at 36 sites in Austria, Czech Republic
and the USA (June 2003 to July 2004). Institutional review boards
or ethics committees approved the protocol at each centre. All
patients gave written consent, and the study was conducted in
accordance with the Declaration of Helsinki.
Patients were randomised 1:1 using an interactive voice
randomisation service to lyophilised subcutaneous certolizumab
pegol 400 mg or placebo (sorbitol solution) every 4 weeks from
baseline to week 20. Solutions of active drug or placebo were
prepared by the pharmacist or other unblinded, qualified site
personnel, before distributing to blinded study personnel for
administration. Patients who completed the study or withdrew
on/after week 12 were eligible and encouraged to enter an open
label study of certolizumab pegol 400 mg every 4 weeks (unless
withdrawn due to non-compliance or possible treatment-related
adverse events (AEs)). Patients who withdrew after taking >1
study dose were asked to return for an early withdrawal visit.
Efficacy/safety evaluations
Efficacy and safety were assessed at baseline and weeks 1, 2, 4,
8, 12, 16, 20 and 24, with additional safety assessments at 4 and
12 weeks post final dose. Additional plasma samples were taken
at weeks 21 and 22.
The primary efficacy endpoint was ACR20 response at
week 24.
16 Secondary endpoints included ACR50/70 response,
ACR component scores, Disease Activity Score Erythrocyte
Sedimentation Rate 3 (DAS (ESR)3), patient-reported outcomes
(including physical function (Health Assessment Questionnaire
Disability Index (HAQ-DI)),
17 health-related quality of life
(HRQoL), Short-Form 36 item questionnaire (SF-36)
18 19), pain
(100-mm visual analogue scale (VAS) and modified Brief Pain
Inventory (mBPI)) and fatigue (11-point Fatigue Assessment
Scale (FAS)
20)) and safety.
Post hoc analyses included determination of the proportion of
subjects achieving minimal clinically important differences
(MCID) in the following at week 24: HAQ-DI (>0.22 point
decrease from baseline),
21 arthritis pain (>10 point decrease),
22
SF-36 domain (>5 point increase in individual domains),
Physical and Mental Component Summary (PCS and MCS)
scores (>2.5 point increase)
18 19 and FAS (>1 point decrease).
23
Safety was assessed by recording all reported AEs at each visit.
Treatment-emergent AEs were defined as occurring after the
first administration of study drug and up to 12 weeks post final
dose. Serious AEs (SAEs) and serious infections were also
calculated (post hoc) as the number of new cases per 100 patient
years (censored at the time of the first event by preferred term).
Laboratory assessments, vital signs, physical examination and
autoantibody levels were monitored according to predefined
assessment schedules. Plasma concentrations of anti-certolizu-
mab pegol antibodies for all patient samples were measured at a
central laboratory (Covance, Chantilly, Virginia, USA) by an
enzyme-linked immunosorbent assay at each safety assessment;
samples were considered positive if the level was .2.4 units/ml
(lower and upper limits of quantitation were 0.412 and 33.3 mg/
ml). Patients who were antibody positive were assessed for
neutralising antibodies in a cell-based bioassay (Alta Analytical,
San Diego, California, USA).
Statistical analyses
The sample size was based on the expected percent of ACR20
responders; 25% of patients treated with placebo and 50% of
patients treated with certolizumab pegol were expected to
achieve an ACR20 response at week 24. A sample size of 100
patients per treatment group was estimated to have >90%
Figure 1 Patient disposition. Modified
intent to treat (mITT) population: all
randomised patients who had taken at
least one dose of study medication.
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response rate between the treatment groups at a 5%, 2-sided
significance level.
All efficacy analyses were performed on the modified intent
to treat (mITT) population (all randomised patients who had
taken >1 dose of study medication). The actual number of
subjects in the summaries varies slightly from the mITT
numbers due to non-imputable missing data for each parameter.
For the primary analysis, patients were considered ‘‘responders’’
if they achieved an ACR20 response vs baseline at week 24.
Patients who withdrew for any reason were considered non-
responders. The proportion of ACR20 responders/non-respon-
ders at each visit was compared using the Cochran–Mantel–
Haenszel (CMH) test stratified by country. Several sensitivity
analyses of the primary efficacy variable were conducted,
including last observation carried forward (LOCF) analysis.
Analyses of ACR50 and ACR70 responders were carried out in
the same way. Changes from baseline in categorical variables
were analysed using the CMH method stratified by country.
Actual values and change from baseline at each visit were
summarised for continuous variables. Differences in continuous
variables between treatment groups were compared using
analysis of covariance (ANCOVA), with country and treatment
group as factors and baseline score as a covariate. Missing
efficacy measurements were imputed using LOCF where
available.
As part of the post hoc analyses, the proportions of patients
reporting improvements >MCID in patient-reported outcome
measures (HAQ-DI, pain VAS, SF-36 and FAS) were compared
between treatment groups at each visit using a logistic
regression model with treatment as factor and baseline score,
age and gender as covariates. The between-group differences in
the number of withdrawals due to lack of efficacy were tested
using a CMH test stratified by country.
Safety was analysed in the safety population (all randomised
patients who received >1 dose of study drug). Analysis of AEs
included summaries per the Medical Dictionary for Regulatory
Activities (version 5.1) coding terms for system organ class,
higher level and preferred terms; intensity and relationship to
study medication; and by classification as serious or non-
serious. AEs leading to death and withdrawal were also assessed.
RESULTS
Patients
A total of 220 patients with active RA were randomised to
certolizumab pegol 400 mg (n=111) or placebo (n=109), with
76 (68.5%) and 28 (25.7%) patients in each group, respectively,
completing treatment at week 24 (fig 1). Significantly fewer
patients who were treated with certolizumab pegol (21.6%) vs
placebo (68.8%) withdrew due to lack of efficacy (p,0.001).
Patient baseline demographics and disease activity were similar
between treatment arms (table 1).
Although rheumatoid factor (RF) positivity was not an
inclusion criterion for the present study, 100% of enrolled
patients were RF positive using a threshold value of >14 IU/ml
for positivity. A significant number of patients had RF values
between 14 and 15 IU/ml, and if a threshold of 15 IU/ml had
been used, 76.1% and 75.5% of patients treated with placebo
and certolizumab pegol, respectively, would have been con-
sidered RF positive.
Efficacy
Primary endpoint
At week 24, using non-responder imputation, certolizumab
pegol 400 mg every 4 weeks demonstrated a significantly
superior ACR20 response vs placebo (p,0.001; 45.5% vs 9.3%)
(fig 2A). Sensitivity analyses of the primary efficacy variable
demonstrated ACR20 response rates of 49.1% and 13.9% at
week 24, respectively (p,0.001).
Secondary endpoints
ACR50 and ACR70
At week 24, using non-responder imputation, ACR50 and
ACR70 responses were significantly superior for certolizumab
pegol vs placebo (22.7% vs 3.7%; p,0.001; and 5.5% vs 0%,
p(0.05, respectively) (fig 2A).
ACR components
Patients treated with certolizumab pegol experienced statisti-
cally significant improvements in all ACR components at week
24 vs placebo (p(0.05) (table 2, fig 3).
Figure 2 Efficacy of certolizumab pegol: American College of Rheumatology (ACR) response rates (modified intent to treat (mITT) population). A.
Treatment with certolizumab pegol 400 mg was statistically significant vs placebo at week 24 for ACR20 and ACR50 (p,0.001) and ACR70 (p(0.05).
B. ACR20, ACR50 and ACR70 responses with certolizumab pegol 400 mg were statistically significant vs placebo over time (p(0.05 at all time points,
with the exceptions of ACR70 at weeks 1, 2, 4 and 16).
Extended report
Ann Rheum Dis 2009;68:805–811. doi:10.1136/ard.2008.099291 807Disease activity
Least squares mean change from baseline in DAS28 (ESR)3 was
significantly superior for certolizumab pegol 400 mg vs placebo
from week 1 and at all time points through to week 24 (21.5 vs
20.6, respectively) (p,0.001).
Patient-reported outcomes
Physical function: HAQ-DI
Significant and clinically meaningful improvements (least
squares mean change from baseline) in physical function were
reported with certolizumab pegol vs placebo from week 1
(20.23 vs 0.04, respectively) through week 24 (20.36 vs 0.13,
respectively) (table 2 and fig 3C; p,0.001). At week 24, 49% of
patients treated with certolizumab pegol reported clinically
meaningful improvements in physical function vs 12% for
placebo (p,0.001).
Arthritis pain
Significant and clinically meaningful reductions (least squares
mean change from baseline) in arthritis pain (VAS) scores were
observed in the certolizumab pegol arm vs placebo by week 1
(216.7 vs 25.2, respectively), and continued to improve
throughout the study up to week 24 (220.6 vs 1.7, respectively)
(p,0.001; table 2 and fig 3D). At week 24, 47% of patients
treated with certolizumab pegol reported clinically meaningful
reductions in arthritis pain vs 17% for placebo (p,0.001). When
measured by the mBPI scale, pain was significantly reduced vs
placebo by day 2 (p(0.05).
Table 1 Baseline patient demographics and disease activity (mITT population)
Characteristic
Placebo
(n=109)
Certolizumab pegol 400 mg
(n=111)
Age in years, mean (SD) 54.9 (11.6) 52.7 (12.7)
Female, n (%) 97 (89.0) 87 (78.4)
RF positive (>14 IU/ml), n (%) 109 (100.0) 110 (100.0)
Disease duration in years, mean (SD) 10.4 (9.6) 8.7 (8.2)
No of prior DMARDs, mean (SD) 2 (1.25) 2 (1.19)
Prior MTX use, n (%) 89 (81.7) 91 (82.0)
Concurrent use of oral corticosteroids (prednisone equivalent
(10 mg/day), n (%)
64 (58.7) 62 (55.9)
Tender joint count, mean (SD) 28.3 (12.5) 29.6 (13.7)
Swollen joint count, mean (SD) 19.9 (9.3) 21.2 (10.1)
Patient’s Global Assessment of Arthritis, mean (SD) 3.3 (0.77) 3.3 (0.75)
Physician’s Global Assessment of Arthritis, mean (SD) 3.6 (0.62) 3.6 (0.67)
Patient’s assessment of arthritis pain (VAS), mean (SD) 54.8 (20.8) 58.2 (21.9)
HAQ-DI, mean (SD) 1.6 (0.65) 1.4 (0.63)
DAS28(ESR)3, mean (SD) 6.3 (0.9) 6.3 (1.1)
CRP (mg/litre), geometric mean (95% CI) 11.3 (8.6 to 14.9) 11.6 (9.1 to 14.9)
ESR (mm/h), geometric mean (95% CI) 35.6 (30.9 to 41.0) 30.9 (25.9 to 36.8)
Patient’s and Physician’s Global Assessments of Arthritis were scored on a categorical scale of 1–5 where 1=very good
(asymptomatic and no limitation of normal activities) and 5=very poor (very severe symptoms that are intolerable and inability to
carry out all normal activities).
CRP, C-reactive protein; DAS28(ESR)3, disease activity score, erythrocyte sedimentation rate 3; DMARD, disease-modifying
antirheumatic drug; HAQ-DI, Health Assessment Questionnaire Disability Index; mITT, modified intent to treat; RF, rheumatoid
factor; VAS, visual analogue scale.
Table 2 Improvement in ACR components and disease activity at weeks 1 and 24: least squares mean change from baseline (mITT population)
Week 1 Week 24
Placebo (n=109) CZP 400 mg (n=111) p Value Placebo (n=109) CZP 400 mg (n=111) p Value
ACR core component scores:
Swollen joint count* 22.8 26.0 ,0.001 26.3 211.6 ,0.001
Tender joint count{ 24.6 29.8 ,0.001 27.3 216.0 ,0.001
Patient’s Global Assessment of Arthritis{ 20.1 20.5 ,0.001 0.0 20.7 ,0.001
Physician’s Global Assessment of Arthritis{ 20.1 20.7 ,0.001 20.2 21.1 ,0.001
Patient’s assessment of arthritis pain
(VAS)1
25.2 216.7 ,0.001 1.7 220.6 ,0.001
HAQ-DI" 0.04 20.23 ,0.001 0.13 20.36 ,0.001
Disease activity:
CRP (mg/litre)** 1.0 0.2 ,0.001 1.2 0.5 ,0.001
ESR (mm/h)** 1.0 0.7 ,0.001 1.0 0.8 0.05
From analysis of covariance model with treatment and country as factors and baseline value as covariate. This table is based on the last observation carried forward approach. The
reported changes for CRP at week 24 correspond to an actual decrease from baseline of 25.2 mg/litre for the certolizumab pegol arm and an increase of +2.2 mg/litre for the
placebo arm, respectively.
*Scale ranged from 0 to 66, with negative change indicating improvement; {scale ranged from 0 to 68, with negative change indicating improvement; {scale ranged from 1 to 5,
with negative change indicating improvement; 1scale ranged from 0 to 100, with negative change indicating improvement; MCID=210; "scale ranged from 0 to 3, with negative
change indicating improvement; MCID=20.22; **based on log-transformed data for CRP and ESR.
ACR, American College of Rheumatology; CRP, C-reactive protein; CZP, certolizumab pegol; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire
Disability Index; MCID, minimal clinically important difference; mITT, modified intention to treat; VAS, visual analogue scale.
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Patients receiving certolizumab pegol reported statistically
significant improvements in HRQoL at week 24 vs placebo,
including all eight SF-36 domains and PCS and MCS scores
(p,0.001) (data not shown). At week 24, significantly more
patients treated with certolizumab pegol reported HRQoL
MCIDs (in all eight domains) vs placebo (p(0.01) (data not
shown). At week 24, 46% and 34% of patients treated with
certolizumab pegol experienced PCS and MCS MCIDs, respec-
tively, vs 16% and 7% for placebo (p,0.001).
Fatigue
Statistically significant and clinically meaningful improvements
in FAS scores were achieved throughout the 24-week study:
least squares mean change from baseline in FAS was 21.69 for
certolizumab pegol vs 20.27 for placebo at week 24 (p,0.001).
At week 24, 46% of patients treated with certolizumab pegol
reported improvements in fatigue of >MCID vs 17% for
placebo (p,0.001).
Kinetics of response
Rapid improvement with certolizumab pegol was observed in
multiple measures, including ACR20 and ACR50 responses
(LOCF imputation; fig 2B), ACR core components (table 2 and
fig 3), DAS28, SF-36 and FAS. At week 4 (ie, after a single 400-
mg dose), mean tender joint count was reduced from baseline
by approximately 40% (from 29.6 to 17.7) with certolizumab
pegol vs 14% with placebo (from 28.3 to 24.2); mean swollen
joint count was reduced by approximately 38% (from 21.2 to
13.1) vs 16% (from 19.9 to 16.7), respectively (fig 3A,B).
Safety
Treatment-emergent AEs occurred in 57.8% and 75.7% of
patients in the placebo and certolizumab pegol groups,
respectively (table 3). The majority of AEs in both treatment
groups were mild or moderate.
AEs reported in >5% of patients in the certolizumab pegol
groups were headache, nasopharyngitis, upper respiratory tract
infections, diarrhoea and sinusitis. SAEs were reported in 3
(2.8%) patients in the placebo group (1 case (0.9%) each of
vomiting, chronic renal failure and pneumonitis) and 8 (7.2%)
patients in the certolizumab pegol group (2 (1.8%) cases of
aggravated RA and 1 (0.9%) each of bacterial arthritis, mastitis,
benign parathyroid tumour, postural dizziness, ischaemic stroke
and menometrorrhagia) (9 vs 18 cases per 100 patient years,
respectively). No cases of tuberculosis or opportunistic infec-
tions were reported. The incidence of serious infections was 0%
with placebo and 1.8% (two cases) with certolizumab pegol
Figure 3 Least squares mean change from baseline in American College of Rheumatology (ACR) core component scores (modified intent to treat
(mITT) population). Least squares mean change from baseline in (A) tender joint count, (B) swollen joint count, (C) Health Assessment Questionnaire
Disability Index (HAQ-DI) and (D) patient’s assessment of arthritis pain (100-mm visual analogue scale (VAS)) were all statistically significantly superior
for certolizumab pegol 400 mg vs placebo from week 1 following administration of study drug and at all time points throughout the 24-week study
period (p(0.01).
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serious infections in the certolizumab pegol group were bacterial
arthritis and mastitis.
There were no reported tumours in the placebo group and
two (1.8%), both benign, with certolizumab pegol (one case
each of uterine fibroids and benign parathyroid tumour). No
malignancies, including lymphoma, or cases of demyelinating
disease were reported. AEs leading to withdrawal were reported
in two (1.8%) patients treated with placebo (nausea, pneumo-
nitis) and five (4.5%) patients treated with certolizumab pegol
(bacterial arthritis, salmonella arthritis, increased blood creati-
nine/increased blood urea, ischaemic stroke, menorrhagia). No
deaths were reported.
Injection site pain was reported in 1.8% and 0% of patients
receiving placebo and certolizumab pegol, respectively. Injection
site reactions occurred in 13.8% and 4.5% of patients,
respectively. Of the patients who received active treatment
and had detectable anti-certolizumab pegol antibodies at any
time during the study, nine (8.1%) had neutralising antibodies
to certolizumab pegol. Clinical studies have demonstrated that
in subjects receiving certolizumab pegol, the ACR20 response
rate at week 24 was reduced in the population as a whole by
approximately 5% as a result of anti-certolizumab pegol
antibody formation in subjects receiving certolizumab pegol
400 mg as monotherapy.
No cases of systemic lupus erythaematosus (SLE) or SLE-like
disease were reported. Antinuclear autoantibodies (ANA) titres
from baseline to week 24 or withdrawal increased in 17% of
patients treated with certolizumab pegol compared with 11% of
patients treated with placebo, with the majority of patients in
both groups (71% and 80%, respectively) showing no change in
ANA titres during the 24-week study.
DISCUSSION
This study demonstrated the efficacy of subcutaneous certoli-
zumab pegol 400 mg monotherapy (administered every
4 weeks) in treating the signs and symptoms of active RA in
patients who had failed treatment with >1 DMARD, with
45.5% of patients treated with certolizumab pegol achieving an
ACR20 response by week 24 vs only 9.3% of patients treated
with placebo.
The response to certolizumab pegol was rapid, as significantly
more patients achieved ACR20 responses (as well as all other
responses, including patient-reported outcomes) as early as
week 1 of treatment compared with placebo. Clinical responses
were durable and sustained through to week 24. Significantly
fewer patients on certolizumab pegol (21.6%) withdrew due to
lack of efficacy compared with placebo (68.8%), and withdrawal
rates were similar to those observed in previous monotherapy
trials.
21 42 4 Certolizumab pegol has also been shown to be
effective when used in combination with MTX every 2 weeks,
with an ACR20 response rate of ,60%.
91 0
Improvements in patient-reported outcomes observed with
certolizumab pegol were clinically meaningful, as demonstrated
by the proportion of patients with changes >MCIDs for the
HAQ-DI, SF-36, pain VAS and FAS. Treatments that reduce
RA-related pain and fatigue are important because these
symptoms are often cited by patients as having a negative
impact on their everyday lives, leading to reduced physical and
social function, anxiety and depression, disrupted leisure
activities and limitations in employment.
20 25 26
Certolizumab pegol was associated with a low incidence of
discontinuation due to AEs (4.5%). The rate of serious
infections was 1.8% for certolizumab pegol vs 0% for placebo.
There were no reports of tuberculosis, opportunistic infections,
malignancy (including lymphoma), demyelinating disease or
congestive heart failure in either group. The incidence of
injection site reactions (4.5%) was low with certolizumab
pegol; the incidence of injection site pain (0%) was also low and
comparable with placebo. Overall, within the limited of
duration of exposure, the AE profile for certolizumab pegol is
consistent with other TNFa inhibitors.
13 14
Nine (8.1%) patients developed neutralising antibodies to
certolizumab pegol. These results are consistent with data
reported for other anti-TNFa agents. Formation of antibodies to
adalimumab or infliximab have been reported in ,5% and
,10%, respectively, of adult patients with RA, and patients
who were adalimumab antibody or infliximab antibody positive
were more likely to have reduced efficacy.
27 28 The ACR20
response rate at week 24 was reduced by only approximately 5%
in patients who developed anti-certolizumab pegol antibodies vs
the whole population. No autoimmune clinical manifestations
(eg, lupus-like syndrome) were observed.
Clinical trials with etanercept
29 or adalimumab,
30 and
observational studies,
31 have suggested that using an anti-
TNFa agent in combination with MTX is more effective than
anti-TNFa monotherapy. Unfortunately, a sizeable subset of
patients with RA is intolerant to, or has a contraindication to
use of MTX and for these individuals anti-TNF monotherapy
can be an important therapeutic option.
The results of this study, demonstrating the efficacy and
safety of subcutaneous certolizumab pegol 400 mg every
Table 3 Treatment-emergent adverse events (AEs), including serious AEs (safety population)
Placebo (n=109)
n (%)
Certolizumab pegol 400 mg (n=111)
n (%)
Any AEs 63 (57.8%) 84 (75.7%)
Intensity:
Mild 43 (39.4%) 62 (55.9%)
Moderate 40 (36.7%) 52 (46.8%)
Severe 11 (10.1%) 8 (7.2%)
Serious AEs 3 (2.8%) 8 (7.2%)
Cases/100 patient years* 9 18
Serious infections 0 (0%) 2 (1.8%)
Cases/100 patient years* 0 4
AEs leading to death 0 (0%) 0 (0%)
AEs leading to withdrawal 2 (1.8%) 5 (4.5%)
*Number of new cases per 100 patient years, calculated as the number of patients with the event under consideration divided by
total exposure (censored at the time of the first event for those with an event under consideration).
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the use of anti-TNFa monotherapy as an effective treatment
option for patients with RA who cannot tolerate or who have a
contraindication to MTX. As the first subcutaneous anti-TNFa
agent shown to be effective at once-monthly dosing, certolizu-
mab pegol provides an effective overall treatment for patients
with RA, with a rapid, meaningful and durable clinical response
and an acceptable safety profile.
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